Sept 26 (Reuters) - EMA:
* EMA RECOMMENDS SUSPENSION OF SICKLE CELL DISEASE MEDICINE OXBRYTA
* EMA: CHMP CONSIDERED THAT DATA FROM ONGOING EMA REVIEW RAISE SERIOUS CONCERNS ABOUT SAFETY OF OXBRYTA DUE TO INCREASED UNCERTAINTIES
Further company coverage:
((Reuters.Briefs@thomsonreuters.com;;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments